The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

Is retail ready for the always-on consumer? Salsify, the platform empowering brand manufacturers, distributors, and retailers to win on the digital shelf, reveals in its 2025 Consumer Research Report ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

SoftBank Robotics America (SBRA), the North American arm of the global leader in robotics solutions announced today that it had received the highest recognition and certification ? Platinum Service ...

UnitedHealth Group has named the head of its Medicare business as the CEO of its insurance business, succeeding the Brian Thompson, who was shot and killed on Dec. 4 in New York City while walking to ...